Expression of CD95 and granzyme B is associated with CD8+ T cell activation and tumor cell killing, whereas activation of the programmed cell death ligand 1 (PD-L1)/PD-1 pathway leads to inhibition of T cell activation (12). This evidence concerns the gene CD8A and neoplasm.